$MAIA News

MAIA Biotechnology Reports 90.5% Disease Control Rate In Phase 2 THIO-101 Clinical Trial Of Ateganosine For Advanced Non-Small Cell Lung Cancer

MAIA Biotechnology Completes Global Enrollment In Part C Of Its Phase 2 THIO-101 Expansion Study Of Ateganosine To Treat Advanced Non-Small Cell Lung Cancer

MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University

MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial

MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial

MAIA Biotechnology Provides A Patient Enrollment Update For Its Ongoing Pivotal Phase 3 Trial, THIO-104; 29 Patients Have Been Dosed Among 34 Activated Trial Sites In 6 Foreign Countries

MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion

MAIA Biotechnology Receives FDA IND Clearance To Expand THIO-101 Phase 2 NSCLC Trial In U.S. With Ateganosine; Updates Manufacturing Protocols Supporting Potential Accelerated Approval Pathway

MAIA Biotechnology Announces Open Market Purchases by CEO and Director

MAIA Biotechnology Insiders Founder/CEO Vlad Vitoc, M.D. And Director Stan V. Smith, Ph.D. Increase Ownership Position Through Open Market Purchases Of ~147,700 Shares Worth ~$201K

MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology

MAIA Biotechnology Announces That It Delivered A Poster Presentation Featuring The Methodology And Study Design For Its Pivotal Phase 3 Clinical Trial On May 31 At The 2026 Annual Meeting Of The American Society Of Clinical Oncology

Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)

MAIA Biotechnology Q1 EPS $(0.14) Beats $(0.18) Estimate

MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer

MAIA Biotechnology Activates First Clinical Facility In U.S. In Its Phase 2 THIO-101 Expansion Study To Treat Non-Small Cell Lung Cancer

MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy

MAIA Biotechnology Expects $33M In Proceeds From Public Offering To Fully Fund Phase 3 Clinical Trial For Non-Small Cell Lung Cancer Treatment Ateganosine

MAIA Biotechnology Expects $33M In Proceeds From Public Offering To Fully Fund Phase 3 Clinical Trial For Non-Small Cell Lung Cancer Treatment Ateganosine

MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer